186 related articles for article (PubMed ID: 23184143)
1. Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model.
On NH; Mitchell R; Savant SD; Bachmeier CJ; Hatch GM; Miller DW
J Neurooncol; 2013 Jan; 111(2):133-43. PubMed ID: 23184143
[TBL] [Abstract][Full Text] [Related]
2. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach.
Percy DB; Ribot EJ; Chen Y; McFadden C; Simedrea C; Steeg PS; Chambers AF; Foster PJ
Invest Radiol; 2011 Nov; 46(11):718-25. PubMed ID: 21788908
[TBL] [Abstract][Full Text] [Related]
3. Selective permeabilization of the blood-brain barrier at sites of metastasis.
Connell JJ; Chatain G; Cornelissen B; Vallis KA; Hamilton A; Seymour L; Anthony DC; Sibson NR
J Natl Cancer Inst; 2013 Nov; 105(21):1634-43. PubMed ID: 24108809
[TBL] [Abstract][Full Text] [Related]
4. Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide.
On NH; Kiptoo P; Siahaan TJ; Miller DW
Mol Pharm; 2014 Mar; 11(3):974-81. PubMed ID: 24495091
[TBL] [Abstract][Full Text] [Related]
5. Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid.
On NH; Savant S; Toews M; Miller DW
J Cereb Blood Flow Metab; 2013 Dec; 33(12):1944-54. PubMed ID: 24045401
[TBL] [Abstract][Full Text] [Related]
6. Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study.
Côté J; Savard M; Bovenzi V; Dubuc C; Tremblay L; Tsanaclis AM; Fortin D; Lepage M; Gobeil F
Neuropeptides; 2010 Apr; 44(2):177-85. PubMed ID: 20080302
[TBL] [Abstract][Full Text] [Related]
7. In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models.
Leten C; Struys T; Dresselaers T; Himmelreich U
J Neurooncol; 2014 Sep; 119(2):297-306. PubMed ID: 24990826
[TBL] [Abstract][Full Text] [Related]
8. Investigation of blood-brain barrier permeability to magnetite-dextran nanoparticles (MD3) after osmotic disruption in rats.
Rousseau V; Denizot B; Pouliquen D; Jallet P; Le Jeune JJ
MAGMA; 1997 Sep; 5(3):213-22. PubMed ID: 9351025
[TBL] [Abstract][Full Text] [Related]
9. Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke.
Jin AY; Tuor UI; Rushforth D; Kaur J; Muller RN; Petterson JL; Boutry S; Barber PA
BMC Neurosci; 2010 Feb; 11():12. PubMed ID: 20122276
[TBL] [Abstract][Full Text] [Related]
10. Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: toxicity and MR findings.
Roman-Goldstein SM; Barnett PA; McCormick CI; Szumowski J; Shannon EM; Ramsey FL; Mass M; Neuwelt EA
J Comput Assist Tomogr; 1994; 18(5):731-6. PubMed ID: 8089321
[TBL] [Abstract][Full Text] [Related]
11. In vitro blood-brain barrier models using brain capillary endothelial cells isolated from neonatal and adult rats retain age-related barrier properties.
Takata F; Dohgu S; Yamauchi A; Matsumoto J; Machida T; Fujishita K; Shibata K; Shinozaki Y; Sato K; Kataoka Y; Koizumi S
PLoS One; 2013; 8(1):e55166. PubMed ID: 23383092
[TBL] [Abstract][Full Text] [Related]
12. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
13. Late changes in blood-brain barrier permeability in a rat tMCAO model of stroke detected by gadolinium-enhanced MRI.
Morgan CA; Mesquita M; Ashioti M; Beech JS; Williams SCR; Irving E; Cash D
Neurol Res; 2020 Oct; 42(10):844-852. PubMed ID: 32600164
[TBL] [Abstract][Full Text] [Related]
14. Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat.
Fernández-López D; Faustino J; Daneman R; Zhou L; Lee SY; Derugin N; Wendland MF; Vexler ZS
J Neurosci; 2012 Jul; 32(28):9588-600. PubMed ID: 22787045
[TBL] [Abstract][Full Text] [Related]
15. Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.
On NH; Chen F; Hinton M; Miller DW
Pharm Res; 2011 Oct; 28(10):2505-15. PubMed ID: 21598079
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.
Brighi C; Reid L; Genovesi LA; Kojic M; Millar A; Bruce Z; White AL; Day BW; Rose S; Whittaker AK; Puttick S
Theranostics; 2020; 10(14):6361-6371. PubMed ID: 32483457
[TBL] [Abstract][Full Text] [Related]
17. Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping.
Taheri S; Gasparovic C; Shah NJ; Rosenberg GA
Magn Reson Med; 2011 Apr; 65(4):1036-42. PubMed ID: 21413067
[TBL] [Abstract][Full Text] [Related]
18. Acute Effects of Viral Exposure on P-Glycoprotein Function in the Mouse Fetal Blood-Brain Barrier.
Bloise E; Petropoulos S; Iqbal M; Kostaki A; Ortiga-Carvalho TM; Gibb W; Matthews SG
Cell Physiol Biochem; 2017; 41(3):1044-1050. PubMed ID: 28222448
[TBL] [Abstract][Full Text] [Related]
19. Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption.
Yang W; Barth RF; Carpenter DE; Moeschberger ML; Goodman JH
Neurosurgery; 1996 May; 38(5):985-92. PubMed ID: 8727825
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
